SEC Form 4 · accession 0001209191-18-036747
Ovid Therapeutics Inc. · OVID
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Karen Bernstein
Director
Period of report
Jun 7, 2018
Accepted (ET)
Jun 8, 2018 · 5:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001636651
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $8.12 | Jun 7, 2018 | A | 5,813 | A | — | Jun 6, 2028 | Common Stock | 5,813 | 5,813 | D |
Explanation of responses
- F1The option will vest in full on June 7, 2019, subject to the Reporting Person's continuous service through such vesting date.